ClinicalTrials.gg
CompletedNCT06576765Updated Nov 10, 2026

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

A Phase 1 interventional study of AZD0780 in Hepatic Impairment, sponsored by AstraZeneca. Completed at 3 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of AZD0780 with moderate and possibly mild hepatic impairment in comparison to a matched healthy control group.

Read the detailed description

This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD0780 dose 1 administered orally to male and female participants (females of non-childbearing potential) with moderate hepatic impairment and mild hepatic impairment (optional) compared with male and female participants (females of non-childbearing potential) with normal hepatic function.

Participants will be enrolled within the following groups based on their Child Pugh classification score as determined at screening:

  • Group 1: Participants with moderate hepatic impairment (Child Pugh Class B, score of 7 to 9).
  • Group 2: Participants with normal hepatic function demographically matched by sex, age, and body mass index (BMI) to the impaired participants.
  • Group 3 (optional): Participants with mild hepatic impairment (Child Pugh Class A, score of 5 or 6).
02

Conditions studied

  • Hepatic Impairment

Keywords

  • Hepatic Impairment
  • Healthy participants
  • AZD0780
  • Pharmacokinetics
  • Safety
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 85 years of age, inclusive at screening

For participants with normal hepatic function:

  • Participant must be medically healthy with no medical history, physical examination, clinical laboratory profiles, vital signs, or 12-lead ECGs, as deemed by the investigator at screening and Day -1.

For participants with hepatic impairment:

  • Participant must have a diagnosis of chronic (≥ 6 months) and stable hepatic impairment at screening and Day -1.
  • Supporting documents confirming the participant's hepatic impairment must be available
  • Participants must be stable on a concomitant medication and/or treatment regimen. Minor changes in dosage can be accepted at the discretion of the investigator.
  • Male participants:
  • Males must be surgically sterile or using, in conjunction with their female partner, a highly effective method of for the duration of the study (from the time of study intervention administration) until 3 months after discharge to prevent pregnancy in a partner.
  • Female participants of non-:
  • Female participants must not be pregnant and must have a negative pregnancy test at screening and check-in, must not be lactating, and must not be of childbearing potential.

Exclusion criteria

Exclusion Criteria:

For participants with normal hepatic function:

  • Any disease or disorder (eg, cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal including bone fractures, endocrine including adrenal insufficiency, metabolic, malignant, psychiatric, major physical impairment)
  • Use of any prescription or non-prescription drugs within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) before study intervention, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study.

For participants with hepatic impairment:

  • Presence of unstable medical (eg, diabetes) or psychological conditions, or any evidence of additional severe or uncontrolled systemic disease (eg, currently unstable or uncompensated renal, cardiovascular, or respiratory disease) or laboratory finding which, in the opinion of the investigator, would compromise the participant's safety or successful participation in this study.
  • Participant has evidence of hepatorenal syndrome or \< 60 mL/minute as calculated using the Cockcroft-Gault equation.
  • Blood dyscrasias with increased risk of bleeding including idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura or symptoms of increased risk of bleeding (frequent bleeding gums or nose bleeds) at screening or Day -1.
  • Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period.
  • Presence of a hepatocellular carcinoma or acute liver disease caused by an infection or drug toxicity.
  • Hepatic impairment due to non-liver disease (eg, right HF).
  • Biliary obstruction or other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver.
  • Clinically relevant hepatic encephalopathy (Grade 2 or more) at screening or Day -1.
  • Current functioning organ transplant or anticipated to receive organ transplant within 2 months of screening or Day -1.
  • Has required new medication for hepatic encephalopathy within the 3 months prior to Day -1.
  • Use of concurrent medication which affects creatinine clearance (eg, cephalosporin antibiotics, ascorbic acid, trimethoprim, cimetidine, or quinine) within 7 days of Day -1.
  • Current or previous treatment with drugs for reduction or inhibition of PCSK9 (eg, evolocumab, alirocumab, or inclisiran).
  • Use of moderate/strong inhibitors or inducers of /5.
  • Unable to refrain from potassium binders, phosphate binders (eg, aluminium hydroxide and calcium carbonate), cholestyramine/colestipol, and ranitidine/nizatidine within 10 hours before and 10 hours after study intervention.
  • Receiving or has received within 14 days of screening, medication that contains a black box warning for significant . A list of prohibited medications can be found in the protocol.
  • Unable to refrain from lactulose within 10 hours before and 10 hours after study intervention.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Group 1

    Subjects with Moderate Impairment will receive a single oral dose of AZD0780 under fasted conditions.

    Drug: AZD0780

  • Experimental
    Group 2

    Healthy participants will receive a single oral dose of AZD0780 under fasted conditions.

    Drug: AZD0780

  • Experimental
    Group 3 (optional)

    Subjects with Mild Impairment will receive a single oral dose of AZD0780 under fasted conditions.

    Drug: AZD0780

Interventions

  • Dose 1

    Also known as: Dose 1

06

What researchers measure

Primary outcomes

  1. AUClast

    Area under plasma concentration-time curve from time zero to the last measurable concentration

    Time frame: Day 1 to Day 11

  2. AUCinf

    Area under plasma concentration-time curve from zero to infinity

    Time frame: Day 1 to Day 11

  3. Cmax

    Maximum observed plasma concentration

    Time frame: Day 1 to Day 11

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    To assess the safety and tolerability of a single oral dose of AZD0780 in participants with moderate and mild (optional) hepatic impairment and those with normal hepatic function

    Time frame: Day 1 to Day 11

  2. Number of participants with abnormal Vital signs, abnormal ECGs, and abnormal physical examination findings

    To assess the safety and tolerability of a single oral dose of AZD0780 in participants with moderate and mild (optional) hepatic impairment and those with normal hepatic function

    Time frame: Day 1 to Day 11

  3. Number of participants with abnormal laboratory tests results

    To assess the safety and tolerability of a single oral dose of AZD0780 in participants with moderate and mild (optional) hepatic impairment and those with normal hepatic function

    Time frame: Day 1 to Day 11

  4. Tmax

    Time to reach maximum observed plasma concentration

    Time frame: Day 1 to Day 11

  5. PK parameters (t1/2λz)

    Terminal elimination half-life

    Time frame: Day 1 to Day 11

  6. PK parameters (CL/F)

    Apparent plasma clearance

    Time frame: Day 1 to Day 11

  7. PK parameters (Vz/F)

    Apparent volume of distribution during the terminal phase

    Time frame: Day 1 to Day 11

  8. PK parameters (AUC0-96)

    Area under the plasma concentration-time curve from time zero to 96 hours

    Time frame: Day 1 to Day 5

  9. PK parameters (CLR)

    Renal clearance of drug from plasma

    Time frame: Day 1 to Day 11

  10. PK parameters (Ae)

    Amount excreted in urine

    Time frame: Day 1 to Day 11

  11. PK parameters (fe)

    Fraction of dose excreted in urine

    Time frame: Day 1 to Day 11

Other outcomes

  1. Multi-omics Analysis

    To explore how multi-omics variations, including genetics, may affect clinical parameters, risk, and prognosis of diseases and the response to medications. Exploratory endpoints are related to the data generated from multi-omics analysis, including genetics, which may be part or all of the participant's genetic information.

    Time frame: Day 1

07

Study locations

3 sites
  • Research Site
    Hialeah, Florida 33014, United States
  • Research Site
    Orlando, Florida 32809, United States
  • Research Site
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Nov 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Aug 29, 2024
StartActual
Aug 8, 2024
Primary completionActual
Nov 8, 2024
CompletionActual
Nov 8, 2024
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and references
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06576765
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Aug 8, 2024
Primary completion
Nov 8, 2024
Completion
Nov 8, 2024
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Laroprovstat

Start the discussion